Change of Adviser

RNS Number : 2566S
Eden Research plc
29 November 2012
 



 29 November 2012

 

EDEN RESEARCH PLC

("Eden" or "Company")

  

Change of adviser

 

Eden Research Plc, the AIM listed agrochemical and encapsulation development company, is pleased to announce that it has appointed WH Ireland as its nominated adviser and broker with immediate effect.

 

 

Enquiries:

 

Eden Research plc          

www.edenresearch.com

Clive Newitt, Managing Director

Tel: 01993 862 761

Alex Abrey, Chief Financial Officer




W H Ireland Limited      

www.wh-ireland.co.uk

John Wakefield / Marc Davies

Tel: 0117 945 3471



Walbrook PR Ltd

Tel: 020 7933 8780

Paul McManus (Media Relations)

Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com

Paul Cornelius (Investor Relations)

Mob: 07827 879 496 or paul.cornelius@walbrookir.com

 

 

Notes:

 

Eden has developed a terpene-based encapsulation technology which uses yeast cells to deliver a slow release of natural compounds for agricultural and non-agricultural uses.

 

Terpenes are natural compounds which function as defence mechanisms in many plant groups and are released in response to infection, attack by pests, stress or mechanical injury. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries.

 

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

 

The next-generation encapsulation technology, licensed from University of Massachusetts Medical School ("UMMS") recently, provides significant additional benefits to the original system as it allows release to be controlled by environmental factors rather than relying solely upon the chemistry of the substances used. This means that there is more control over the timing of the release of the active compound being carried allowing for further reduction in chemicals applied whilst ensuring maximum effectiveness.

 

The UMMS license also significantly expands the potential use of the Eden technology in non-agricultural applications such as health and beauty, cosmetics and animal health.

 

For more information about Eden, please visit www.edenresearch.com 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
APPLLFSRLLLTFIF
UK 100

Latest directors dealings